Q-omics provides the consensus-scored ERN1 profile across patient tissues and cancer cell-line models. ERN1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ERN1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ERN1 RNA expression shows 20,732 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KIRC, and UVM as cancer lineages where ERN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERN1 survival associations across molecular data types. ERN1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERN1 RNA expression–survival associations across cancer types. High ERN1 expression shows unfavorable associations in ACC, KIRP, CESC, KICH and LUSC, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ERN1 RNA expression.
This table summarizes ERN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ERN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERN1 shows lower tumor expression in LUSC, KICH and UCEC and higher tumor expression in KIRC, KIRP and STAD. The KIRC box plot shows higher ERN1 RNA expression in tumor versus normal tissue (log2 FC = +0.600, t-test p < 0.001).
This table shows molecular features associated with ERN1 in patient tissues and cancer cell lines. In patient samples, ERN1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ERN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and UPPER_AERODIGESTIVE_TRACT.
